Drug intelligence / Profile preview

IPVAX

Development stage: Unknown
Lead developer: Boryung Biopharma
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular, Subcutaneous

Overview

IPVAX is an enhanced inactivated poliovirus vaccine (eIPV) developed and distributed by Boryung Biopharma in South Korea, utilizing bulk vaccine material imported from the Netherlands Vaccine Institute (NVI). It is a trivalent vaccine containing inactivated strains of poliovirus types 1, 2, and 3. The vaccine is indicated for active immunization to prevent poliomyelitis (polio) and is typically administered as a three-dose primary series at 2, 4, and 6 months of age via intramuscular or subcutaneous injection. Clinical data indicates high immunogenicity with 100% seroconversion for all three types and a safety profile comparable to other WHO-prequalified inactivated polio vaccines.

Brand names: IPVAX
Other names: eIPVInactivated Polio VaccineBoryung IPV

Beyond the preview

Go deeper on IPVAX.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IPVAX.

Explore the full profile